Helix BioPharma Corp.
Helix BioPharma Corp.
Your view on HBPCF
Overview
What the company does, where it operates, and who runs it.
About Helix BioPharma Corp.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Thomas Mehrling
- Headquarters
- 401 Bay Street, Toronto, ON, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Thomas Mehrling
- Headquarters
- 401 Bay Street, Toronto, ON, CA
Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2.
It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.
The company is headquartered in Toronto, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Helix BioPharma Corp., and the rating behind it. HBPCF last traded at $1.73; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Helix BioPharma Corp.. Starting points for Helix BioPharma Corp.: EPS -$0.04, beta -0.35 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Helix BioPharma Corp.. Helix BioPharma Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Helix BioPharma Corp.. Trailing twelve-month EPS for Helix BioPharma Corp. stands at -$0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Helix BioPharma Corp.. Helix BioPharma Corp. has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Helix BioPharma Corp. valued side by side against its closest peers. Helix BioPharma Corp. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Helix BioPharma Corp., and how their positions are changing. At a $132.1M market value, institutional positions materially move Helix BioPharma Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Helix BioPharma Corp. executives and directors. Shares of Helix BioPharma Corp. have traded between $0.45 and $1.73 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Helix BioPharma Corp.. Helix BioPharma Corp. is a $132.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Helix BioPharma Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Helix BioPharma Corp.. Coverage tracks Helix BioPharma Corp. within Biotechnology (Healthcare). Press releases and market coverage, newest first.